According to data released by GLOBOCAN 2020, lung cancer is currently the most prevalent malignant tumor with the highest mortality rate in China. Small ce...
Neumora Therapeutics, Inc. (Neumora), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the planned init...
The initiative combines Proscia’s innovative digital pathology software platform Concentriq Dx and Leica Biosystems’ scanner hardware. Proscia&...
"Blood cancers are a complex, heterogeneous set of diseases and while the treatment landscape has advanced in recent years, there is still a lot we don't k...
Capital Rx, the health technology company changing the way prescription drugs are priced and patients are cared for, and type 2 diabetes (T2D) r...
Versanis' lead asset is bimagrumab, a monoclonal antibody that binds activin type II A and B receptors to block activin and myostatin signaling. Bimagrumab...
GSK plc (LSE/NYSE: GSK) today announced it has started shipping doses of its quadrivalent influenza vaccines to US healthcare providers and pharmacies in p...
Phase III OCARINA II trial met primary and secondary endpoints OCREVUS twice a year, 10-minute injection has the potential to further improve the treatm...
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases and ArriVent Bi...
Stanford University joins more than 20 healthcare and hospital systems currently enrolling patients in the PREDAPT Trial with an approved protocol to study...
Expansion of capabilities provides customised bioconjugation solutions for Pharma and IVD industries. Biosynth, a supplier of critical raw materials to th...
Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a producer of technologically advanced healthcare products and services, ...
FOCUS (Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol) is a Phase 3, randomized, double-blind, placebo-controlled, multicenter...
Under the terms for the line of credit, IGC can draw up to $1 million within a 30-day period. The interest rate for a draw is 1% plus the rate paid on cert...
© 2025 Biopharma Boardroom. All Rights Reserved.
